Brokerages expect that Humana Inc (NYSE:HUM) will report sales of $18.67 billion for the current quarter, according to Zacks. Six analysts have provided estimates for Humana's earnings, with the lowest sales estimate coming in at $18.28 billion and the highest estimate coming in at $18.96 billion. Humana posted sales of $16.24 billion in the same quarter last year, which suggests a positive year-over-year growth rate of 15%. The business is expected to report its next earnings report before the market opens on Tuesday, November 3rd.
According to Zacks, analysts expect that Humana will report full-year sales of $75.41 billion for the current year, with estimates ranging from $74.63 billion to $75.99 billion. For the next financial year, analysts forecast that the business will post sales of $82.45 billion, with estimates ranging from $81.25 billion to $84.67 billion. Zacks Investment Research's sales calculations are an average based on a survey of analysts that that provide coverage for Humana.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, August 5th. The insurance provider reported $12.56 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $10.34 by $2.22. The company had revenue of $19.08 billion for the quarter, compared to analysts' expectations of $18.66 billion. Humana had a net margin of 4.96% and a return on equity of 26.70%. Humana's revenue for the quarter was up 17.5% compared to the same quarter last year. During the same period in the prior year, the business earned $6.05 earnings per share.
Several analysts have issued reports on HUM shares. Stephens upped their target price on Humana from $433.00 to $450.00 and gave the stock an "overweight" rating in a research note on Monday, August 10th. Mizuho upped their target price on Humana from $420.00 to $462.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Royal Bank of Canada upped their target price on Humana from $388.00 to $420.00 and gave the stock a "sector perform" rating in a research note on Monday, August 17th. Sanford C. Bernstein started coverage on Humana in a research note on Thursday, October 1st. They issued a "market perform" rating and a $459.00 target price for the company. Finally, JPMorgan Chase & Co. upped their target price on Humana from $394.00 to $452.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 18th. Eight equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. The company has a consensus rating of "Buy" and a consensus price target of $437.43.
A number of hedge funds have recently made changes to their positions in HUM. Cerebellum GP LLC bought a new position in Humana in the second quarter worth $26,000. Carroll Financial Associates Inc. increased its holdings in shares of Humana by 426.7% during the second quarter. Carroll Financial Associates Inc. now owns 79 shares of the insurance provider's stock valued at $30,000 after acquiring an additional 64 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Humana by 1,187.5% during the second quarter. Exchange Traded Concepts LLC now owns 103 shares of the insurance provider's stock valued at $40,000 after acquiring an additional 95 shares in the last quarter. Global Retirement Partners LLC increased its holdings in shares of Humana by 34.2% during the second quarter. Global Retirement Partners LLC now owns 106 shares of the insurance provider's stock valued at $41,000 after acquiring an additional 27 shares in the last quarter. Finally, Harbor Investment Advisory LLC increased its holdings in shares of Humana by 41.3% during the second quarter. Harbor Investment Advisory LLC now owns 106 shares of the insurance provider's stock valued at $41,000 after acquiring an additional 31 shares in the last quarter. 92.43% of the stock is owned by institutional investors.
HUM stock opened at $433.08 on Tuesday. The stock has a market cap of $57.29 billion, a price-to-earnings ratio of 16.47, a price-to-earnings-growth ratio of 1.84 and a beta of 0.88. The company's 50 day moving average is $411.37 and its 200 day moving average is $391.60. The company has a current ratio of 1.69, a quick ratio of 1.69 and a debt-to-equity ratio of 0.42. Humana has a 1-year low of $208.25 and a 1-year high of $445.20.
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.625 dividend. This represents a $2.50 dividend on an annualized basis and a yield of 0.58%. The ex-dividend date is Tuesday, September 29th. Humana's payout ratio is 13.99%.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Story: What is the LIBOR?
Get a free copy of the Zacks research report on Humana (HUM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
6 Gambling Stocks Ready For a Rebound
If you didn’t believe that gambling stocks are a worthwhile investment, consider this. The Business Research Company projects the global gambling market to reach $565.4 billion through 2022. That assumes that the industry will continue growing at is annual rate of 5.9%.
The gambling industry is composed of many segments. There are casinos, lotteries, and the now legalized segment of sports betting. But gambling is also broken down into offline gambling, online gambling and even virtual reality gambling. In fact, virtual reality gambling is projected to grow at an annual rate of 21.5% until 2022.
But virtual reality is only one of a number of emerging technologies that are changing the “traditional” face of the gambling industry. There are now hybrid games – the combination of online and land-based games and even augmented reality games.
And don’t forget about fantasy sports. Fantasy sports has created an entire industry and it wasn’t created for one person to have bragging rights over their buddies. Fantasy sports is a multi-million industry.
But like many other segments of the economy, gambling stocks were hit hard by the Covid-19 pandemic. Not only were casinos closed, but live sports were also put on hold. This dried up many of the traditional avenues of gambling, and gambling stocks sank lower as a result.
However, the global economy is starting to re-open. And while it was thought that casinos would be one of the last to come back, there are casinos that are starting to re-open. And, it’s becoming more and more likely that there will be live sports (likely without fans initially) sooner rather than later. And that will open up the fantasy sports market.
These stocks tend to move quickly. So now is the time to take action. That’s why we’ve created this special presentation that highlights 6 gambling stocks that are ready for a rebound. The sell-off was real, but so will the comeback. And when it does, these stocks may cost much more than they do now.
View the "6 Gambling Stocks Ready For a Rebound".